{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T18:10:01Z","timestamp":1766167801102,"version":"3.48.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T00:00:00Z","timestamp":1759190400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T00:00:00Z","timestamp":1759190400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Ophthalmol"],"DOI":"10.1007\/s10792-025-03747-4","type":"journal-article","created":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T04:57:15Z","timestamp":1759208235000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparative efficacy of subretinal and intravitreal conbercept injections in polypoidal choroidal vasculopathy"],"prefix":"10.1007","volume":"45","author":[{"given":"Kaiyuan","family":"Xu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaojun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,9,30]]},"reference":[{"key":"3747_CR1","doi-asserted-by":"crossref","unstructured":"Sen P, Manayath G, Shroff D, Salloju V, Dhar P (2023) Polypoidal Choroidal vasculopathy: an update on diagnosis and treatment. Clin Ophthalmol (Auckland, NZ) 1753\u201370","DOI":"10.2147\/OPTH.S385827"},{"issue":"2","key":"3747_CR2","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1097\/APO.0000000000000573","volume":"12","author":"P Ruamviboonsuk","year":"2023","unstructured":"Ruamviboonsuk P, Lai TYY, Chen S-J et al (2023) Polypoidal choroidal vasculopathy: updates on risk factors, diagnosis, and treatments. Asia-Pac J Ophthalmol 12(2):184\u2013195","journal-title":"Asia-Pac J Ophthalmol"},{"issue":"2","key":"3747_CR3","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.oret.2023.11.018","volume":"8","author":"GT Kokame","year":"2024","unstructured":"Kokame GT (2024) Emerging importance of polypoidal choroidal vasculopathy. Ophthalmol Retina 8(2):95\u201397","journal-title":"Ophthalmol Retina"},{"issue":"5","key":"3747_CR4","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1016\/j.survophthal.2023.04.002","volume":"68","author":"A Hatamnejad","year":"2023","unstructured":"Hatamnejad A, Patil NS, Mihalache A et al (2023) Efficacy and safety of anti-vascular endothelial growth agents for the treatment of polypoidal choroidal vasculopathy: a systematic review and meta-analysis. Surv Ophthalmol 68(5):920\u2013928","journal-title":"Surv Ophthalmol"},{"issue":"10","key":"3747_CR5","doi-asserted-by":"publisher","first-page":"1934","DOI":"10.1038\/s41433-021-01773-x","volume":"36","author":"S Liu","year":"2022","unstructured":"Liu S, Chhabra R (2022) Real-world outcomes of combined therapy of photodynamic therapy with anti-vascular endothelial growth factor for polypoidal choroidal vasculopathy. Eye (London) 36(10):1934\u20131939","journal-title":"Eye (London)"},{"key":"3747_CR6","unstructured":"Chhablani JK (2011) The long-term data of photodynamic therapy (PDT) for polypoidal choroidal vasculopathy (PCV). Retina (Philadelphia, Pa.) 31(1):196\u20137"},{"issue":"8","key":"3747_CR7","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1016\/j.drudis.2019.01.023","volume":"24","author":"J Devoldere","year":"2019","unstructured":"Devoldere J, Peynshaert K, De Smedt SC, Remaut K (2019) M\u00fcller cells as a target for retinal therapy. Drug Discov Today 24(8):1483\u20131498","journal-title":"Drug Discov Today"},{"key":"3747_CR8","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics13010108","author":"HM Kim","year":"2021","unstructured":"Kim HM, Woo SJ (2021) Ocular drug delivery to the retina: current innovations and future perspectives. Pharmaceutics. https:\/\/doi.org\/10.3390\/pharmaceutics13010108","journal-title":"Pharmaceutics"},{"issue":"2","key":"3747_CR9","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1007\/s10792-020-01620-0","volume":"41","author":"Y Sahu","year":"2021","unstructured":"Sahu Y, Chaudhary N, Joshi M, Gandhi A (2021) Idiopathic polypoidal choroidal vasculopathy: a review of literature with clinical update on current management practices. Int Ophthalmol 41(2):753\u2013765","journal-title":"Int Ophthalmol"},{"key":"3747_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2020.10.028","volume":"328","author":"S Tavakoli","year":"2020","unstructured":"Tavakoli S, Peynshaert K, Lajunen T et al (2020) Ocular barriers to retinal delivery of intravitreal liposomes: impact of vitreoretinal interface. J Control Release 328:952\u201361","journal-title":"J Control Release"},{"key":"3747_CR11","doi-asserted-by":"crossref","unstructured":"Wang Y, Shen M, Cheng J, Sun X, Kaiser PK (2020) The efficacy of conbercept in polypoidal choroidal vasculopathy: a systematic review. J Ophthalmol 20204924053","DOI":"10.1155\/2020\/4924053"},{"issue":"5","key":"3747_CR12","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1097\/IAE.0000000000002035","volume":"39","author":"Z Huang","year":"2019","unstructured":"Huang Z, Ding Q, Yan M et al (2019) Short-term efficacy of conbercept and ranibizumab for polypoidal choroidal vasculopathy. Retina 39(5):889\u2013895","journal-title":"Retina"},{"issue":"1","key":"3747_CR13","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1186\/s12886-024-03687-0","volume":"24","author":"Y Liu","year":"2024","unstructured":"Liu Y, Guo J, Tang W, Xu G, Liu W (2024) Two-year outcomes of intravitreal conbercept therapy for polypoidal choroidal vasculopathy. BMC Ophthalmol 24(1):441","journal-title":"BMC Ophthalmol"},{"key":"3747_CR14","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S158368","author":"Y Peng","year":"2018","unstructured":"Peng Y, Zhang X, Li M et al (2018) Short-term efficacy of intravitreal conbercept in treatment-naive patients with polypoidal choroidal vasculopathy. Drug Des Devel Ther. https:\/\/doi.org\/10.2147\/DDDT.S158368","journal-title":"Drug Des Devel Ther"},{"key":"3747_CR15","doi-asserted-by":"crossref","unstructured":"Ye LH, Cai Y, Shi X, et al (2021) One-year results of intravitreal conbercept in treatment-na\u00efve subjects with polypoidal choroidal vasculopathy. Graefe's Arch Clin Exp Ophthalmol 259(6):1455\u201362","DOI":"10.1007\/s00417-020-04988-y"},{"key":"3747_CR16","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11164717","author":"C Irigoyen","year":"2022","unstructured":"Irigoyen C, Amenabar Alonso A, Sanchez-Molina J, Rodr\u00edguez-Hidalgo M, Lara-L\u00f3pez A, Ruiz-Ederra J (2022) Subretinal injection techniques for retinal disease: a review. J Clin Med. https:\/\/doi.org\/10.3390\/jcm11164717","journal-title":"J Clin Med"},{"issue":"1","key":"3747_CR17","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1159\/000525412","volume":"66","author":"L Tang","year":"2023","unstructured":"Tang L, Luo D, Qiu Q, Xu GT, Zhang J (2023) Hyperreflective foci in diabetic macular edema with subretinal fluid: association with visual outcomes after anti-VEGF treatment. Ophthalmic Res 66(1):39\u201347","journal-title":"Ophthalmic Res"},{"issue":"8","key":"3747_CR18","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1097\/IAE.0b013e31824f91e8","volume":"32","author":"A Koh","year":"2012","unstructured":"Koh A, Lee WK, Chen LJ et al (2012) EVEREST study: efficacy and safety of verteporfin photodynamic therapy in combination with ranibizumab or alone versus ranibizumab monotherapy in patients with symptomatic macular polypoidal choroidal vasculopathy. Retina 32(8):1453\u20131464","journal-title":"Retina"},{"key":"3747_CR19","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241310535","author":"D Tripepi","year":"2023","unstructured":"Tripepi D, Jalil A, Ally N et al (2023) The role of subretinal injection in ophthalmic surgery: therapeutic agent delivery and other indications. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms241310535","journal-title":"Int J Mol Sci"},{"issue":"12","key":"3747_CR20","doi-asserted-by":"publisher","first-page":"4037","DOI":"10.1007\/s10792-021-01976-x","volume":"41","author":"P Tranos","year":"2021","unstructured":"Tranos P, Tsiropoulos GN, Koronis S, Vakalis A, Asteriadis S, Stavrakas P (2021) Comparison of subretinal versus intravitreal injection of recombinant tissue plasminogen activator with gas for submacular hemorrhage secondary to wet age-related macular degeneration: treatment outcomes and brief literature review. Int Ophthalmol 41(12):4037\u20134046","journal-title":"Int Ophthalmol"},{"issue":"4","key":"3747_CR21","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1016\/j.survophthal.2022.01.006","volume":"67","author":"MR Romano","year":"2022","unstructured":"Romano MR, Rossi T, Borgia A, Catania F, Sorrentino T, Ferrara M (2022) Management of refractory and recurrent macular holes: a comprehensive review. Surv Ophthalmol 67(4):908\u2013931","journal-title":"Surv Ophthalmol"},{"issue":"3","key":"3747_CR22","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.ophtha.2020.07.062","volume":"128","author":"MH Maloney","year":"2021","unstructured":"Maloney MH, Payne SR, Herrin J, Sangaralingham LR, Shah ND, Barkmeier AJ (2021) Risk of systemic adverse events after intravitreal bevacizumab, ranibizumab, and aflibercept in routine clinical practice. Ophthalmology 128(3):417\u2013424","journal-title":"Ophthalmology"},{"issue":"5","key":"3747_CR23","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1007\/s00417-020-04600-3","volume":"258","author":"J Peng","year":"2020","unstructured":"Peng J, Liang T, Chen C et al (2020) Subretinal injection of ranibizumab in advanced pediatric vasoproliferative disorders with total retinal detachments. Graefes Arch Clin Exp Ophthalmol 258(5):1005\u20131012","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"7","key":"3747_CR24","doi-asserted-by":"publisher","first-page":"e795","DOI":"10.1111\/aos.14386","volume":"98","author":"TT Yao","year":"2020","unstructured":"Yao TT, Yang Y, Jin XL et al (2020) Intraocular pharmacokinetics of anti-vascular endothelial growth factor agents by intraoperative subretinal versus intravitreal injection in silicone oil-filled eyes of proliferative diabetic retinopathy: a randomized controlled pilot study. Acta Ophthalmol 98(7):e795\u2013e800","journal-title":"Acta Ophthalmol"},{"key":"3747_CR25","doi-asserted-by":"crossref","unstructured":"V\u00e4h\u00e4tupa M, J\u00e4rvinen TAH, Uusitalo-J\u00e4rvinen H (2020) Exploration of oxygen-induced retinopathy model to discover new therapeutic drug targets in retinopathies. Front Pharmacol 11873","DOI":"10.3389\/fphar.2020.00873"},{"key":"3747_CR26","doi-asserted-by":"crossref","unstructured":"Liu J, Tsang JKW, Fung FKC, Chung SK, Fu Z, Lo ACY (2022) Retinal microglia protect against vascular damage in a mouse model of retinopathy of prematurity. Front Pharmacol 13945130","DOI":"10.3389\/fphar.2022.945130"},{"issue":"4","key":"3747_CR27","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1177\/1120672119832432","volume":"29","author":"Z Papadopoulos","year":"2019","unstructured":"Papadopoulos Z (2019) Aflibercept: a review of its effect on the treatment of exudative age-related macular degeneration. Eur J Ophthalmol 29(4):368\u2013378","journal-title":"Eur J Ophthalmol"},{"key":"3747_CR28","doi-asserted-by":"crossref","unstructured":"Shen Y, Wang H, Xu X, et al. (2022) Metabolomics study of treatment response to conbercept of patients with neovascular age-related macular degeneration and polypoidal choroidal vasculopathy. Front Pharmacol 13991879","DOI":"10.3389\/fphar.2022.991879"},{"key":"3747_CR29","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10050981","author":"JT Cox","year":"2021","unstructured":"Cox JT, Eliott D, Sobrin L (2021) Inflammatory complications of intravitreal anti-VEGF injections. J Clin Med. https:\/\/doi.org\/10.3390\/jcm10050981","journal-title":"J Clin Med"},{"issue":"10","key":"3747_CR30","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.18240\/ijo.2020.10.15","volume":"13","author":"S Akkaya","year":"2020","unstructured":"Akkaya S, A\u00e7\u0131kal\u0131n B, Do\u011fan YE, \u00c7oban F (2020) Subthreshold micropulse laser versus intravitreal anti-VEGF for diabetic macular edema patients with relatively better visual acuity. Int J Ophthalmol 13(10):1606\u20131611","journal-title":"Int J Ophthalmol"},{"key":"3747_CR31","doi-asserted-by":"crossref","unstructured":"Cheng S, Zhang S, Huang M, et al. (2024) Treatment of neovascular age-related macular degeneration with anti-vascular endothelial growth factor drugs: progress from mechanisms to clinical applications. Front Med 111411278","DOI":"10.3389\/fmed.2024.1411278"}],"container-title":["International Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-025-03747-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10792-025-03747-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-025-03747-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T18:06:06Z","timestamp":1766167566000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10792-025-03747-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,30]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3747"],"URL":"https:\/\/doi.org\/10.1007\/s10792-025-03747-4","relation":{},"ISSN":["1573-2630"],"issn-type":[{"type":"electronic","value":"1573-2630"}],"subject":[],"published":{"date-parts":[[2025,9,30]]},"assertion":[{"value":"5 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was approved by the ethics committee of The Second Affiliated Hospital of Nanjing Medical University. Written informed consent was waived due to the retrospective nature of the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The Research Ethics Board approved our request to publish anonymized data for this study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"No informed consent was obtained from participants as data collected were retrospective in nature and part of the standard of care examination. This was approved by the ethics committee of The Second Affiliated Hospital of Nanjing Medical University and adhered to the Tenet\u2019s of Helsinki for retrospective studies.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}],"article-number":"400"}}